Fibrocell Provides Final Data To Resolve FDA Concerns On Its Autologous Stem Cell Therapy For Facial Wrinkles
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech hopes next to advance its technology into treatment of acne scarring; the laViv PDUFA date is June 22.
You may also be interested in...
Missing Mechanism Of Action Dogged Laviv Review
Absence of data about what happens under the surface of the skin when the cell therapy for wrinkles is injected raised safety concerns.
Limited Rollout Planned For Fibrocell's Newly Approved Aesthetic Cellular Therapy
The initial indication for laViv is treatment of nasolabial fold wrinkles, but Fibrocell is eyeing additional indications for its autologous cell therapy.
Limited Rollout Planned For Fibrocell's Newly Approved Aesthetic Cellular Therapy
The initial indication for laViv is treatment of nasolabial fold wrinkles, but Fibrocell is eyeing additional indications for its autologous cell therapy.